Vaishali Pharma [VAISHALI] vs Lotus Eye Hospital [LOTUSEYE] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Vaishali Pharma Ltd. wins in 7 metrics, Lotus Eye Hospital and Institute Ltd. wins in 9 metrics, with 0 ties. Lotus Eye Hospital and Institute Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Vaishali Pharma Ltd. | Lotus Eye Hospital and Institute Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 133.83 | 371.78 | Vaishali Pharma Ltd. |
| Price-to-Book Ratio | 1.57 | 3.79 | Vaishali Pharma Ltd. |
| Debt-to-Equity Ratio | 23.15 | 7.92 | Lotus Eye Hospital and Institute Ltd. |
| PEG Ratio | N/A | 20.45 | N/A |
| EV/EBITDA | -60.31 | 102.16 | Lotus Eye Hospital and Institute Ltd. |
| Profit Margin (TTM) | -0.45% | 1.26% | Lotus Eye Hospital and Institute Ltd. |
| Operating Margin (TTM) | 5.81% | -2.40% | Vaishali Pharma Ltd. |
| EBITDA Margin (TTM) | 5.81% | N/A | N/A |
| Return on Equity | 1.26% | 1.23% | Vaishali Pharma Ltd. |
| Return on Assets (TTM) | 0.74% | 1.06% | Lotus Eye Hospital and Institute Ltd. |
| Free Cash Flow (TTM) | $-183.43M | $-21.28M | Lotus Eye Hospital and Institute Ltd. |
| 1-Year Return | -44.99% | 87.80% | Lotus Eye Hospital and Institute Ltd. |
| Price-to-Sales Ratio (TTM) | 0.92 | 4.79 | Vaishali Pharma Ltd. |
| Enterprise Value | $1.24B | $2.23B | Lotus Eye Hospital and Institute Ltd. |
| EV/Revenue Ratio | 1.09 | 4.31 | Vaishali Pharma Ltd. |
| Gross Profit Margin (TTM) | 1.47% | N/A | N/A |
| Revenue per Share (TTM) | $10 | $25 | Lotus Eye Hospital and Institute Ltd. |
| Earnings per Share (Diluted) | $0.06 | $0.32 | Lotus Eye Hospital and Institute Ltd. |
| Beta (Stock Volatility) | -0.01 | 0.57 | Vaishali Pharma Ltd. |
Vaishali Pharma Ltd. vs Lotus Eye Hospital and Institute Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vaishali Pharma Ltd. | 0.42% | -1.78% | 2.43% | 19.70% | -10.93% | -16.04% |
| Lotus Eye Hospital and Institute Ltd. | 3.61% | 18.71% | 31.36% | 30.60% | 6.44% | 16.21% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vaishali Pharma Ltd. | -44.99% | -44.04% | 83.08% | 68.79% | 68.79% | 68.79% |
| Lotus Eye Hospital and Institute Ltd. | 87.80% | 65.97% | 207.74% | 690.06% | 1,106.25% | 278.96% |
Performance & Financial Health Analysis: Vaishali Pharma Ltd. vs Lotus Eye Hospital and Institute Ltd.
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.05B | ₹2.63B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 871,885 | 18,128 |
| 90 Day Avg. Volume | 455,768 | 13,595 |
| Last Close | ₹7.17 | ₹139.98 |
| 52 Week Range | ₹4.75 - ₹13.59 | ₹67.72 - ₹147.00 |
| % from 52W High | -47.24% | -4.78% |
| All-Time High | ₹24.91 (Oct 14, 2024) | ₹147.00 (Jan 30, 2026) |
| % from All-Time High | -71.22% | -4.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.12% | 0.11% |
| Quarterly Earnings Growth | -0.09% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.01% |
| Operating Margin (TTM) | 0.06% | -0.02% |
| Return on Equity (TTM) | 0.01% | 0.01% |
| Debt to Equity (MRQ) | 23.15 | 7.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹5.11 | ₹31.41 |
| Cash per Share (MRQ) | ₹0.08 | ₹1.62 |
| Operating Cash Flow (TTM) | ₹-326,443,000 | ₹5.77M |
| Levered Free Cash Flow (TTM) | ₹8.17M | ₹7.39M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Vaishali Pharma Ltd. vs Lotus Eye Hospital and Institute Ltd.
| Metric | VAISHALI (Apr 26, 2026) | LOTUSEYE (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 133.83 | 371.78 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | 20.45 |
| Price to Sales (TTM) | 0.92 | 4.79 |
| Price to Book (MRQ) | 1.57 | 3.79 |
| Market Capitalization | ||
| Market Capitalization | ₹1.05B | ₹2.63B |
| Enterprise Value | ₹1.24B | ₹2.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.09 | 4.31 |
| Enterprise to EBITDA | -60.31 | 102.16 |
| Risk & Other Metrics | ||
| Beta | -0.01 | 0.57 |
| Book Value per Share (MRQ) | ₹5.11 | ₹31.41 |
Financial Statements Comparison: Vaishali Pharma Ltd. vs Lotus Eye Hospital and Institute Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | VAISHALI (2025) | LOTUSEYE (2025) |
|---|---|---|
| Revenue/Sales | 978.82M | 486.03M |
| Cost of Goods Sold | 856.75M | 259.50M |
| COGS % of Revenue | 87.5% | 53.4% |
| Gross Profit | 122.07M | 226.53M |
| Gross Margin | 12.5% | 46.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 59.00M | 5.52M |
| Operating Margin | 6.0% | 1.1% |
| EBITDA | 93.22M | 47.35M |
| EBITDA Margin | 9.5% | 9.7% |
| Pre-Tax Income | 12.26M | 13.83M |
| Pre-Tax Income % of Revenue | 1.3% | 2.8% |
| Income Tax | 4.08M | 6.43M |
| Income Tax % of Revenue | 0.4% | 1.3% |
| Net Income (Profit) | 8.17M | 7.39M |
| Profit Margin | 0.8% | 1.5% |
Balance Sheet & Liquidity Metrics
| Metric | VAISHALI (2025) | LOTUSEYE (2025) |
|---|---|---|
| Cash & Equivalents | 17.11M | 20.11M |
| Total Current Assets | 1.04B | 115.70M |
| Total Current Assets % of Revenue | 106.7% | 23.8% |
| Total Current Liabilities | 400.53M | 74.25M |
| Total Current Liabilities % of Revenue | 40.9% | 15.3% |
| Long-Term Debt | 46.19M | 20.27M |
| Long-Term Debt % of Revenue | 4.7% | 4.2% |
| Total Shareholders Equity | 649.16M | 600.00M |
| Retained Earnings | 157.29M | 143.09M |
| Retained Earnings % of Revenue | 16.1% | 29.4% |
| Property, Plant & Equipment | 0 | 442.83M |
Cash Flow Statement Comparison
| Metric | VAISHALI (2025) | LOTUSEYE (2025) |
|---|---|---|
| Operating Cash Flow | -326.44M | 5.77M |
| Operating Cash Flow % of Revenue | -33.4% | 1.2% |
| Capital Expenditures | -3.05M | -47.90M |
| Free Cash Flow | -183.43M | -21.28M |
| FCF Margin | -18.7% | -4.4% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 130.46M | 20.80M |
| Float Shares | 68.14M | 4.56M |
| % Held by Insiders | N/A | 71.94% |
| % Held by Institutions | N/A | 0.00% |
| % Held by Public | N/A | 28.06% |
Dividend Analysis & Yield Comparison: Vaishali Pharma Ltd. vs Lotus Eye Hospital and Institute Ltd.
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.33 |
| 3-Year Avg Dividend Yield | N/A | 0.66% |
| 3-Year Total Dividends | N/A | ₹1.00 |
| Ex-Dividend Date | N/A | Sep 18, 2023 |